Widespread use of Astrazeneca's Brilinta is expected to overshadow the uptake of Eli Lilly/Daiichi Sankyo's rival acute coronary syndrome drug Effient in the US and Europe until 2018, according to a new report.
The Decision Resources report notes that AstraZeneca's Brilinta, which is expected to launch in 2011, will provide greater safety and flexibility in patients who need coronary artery bypass graft surgery.
The drawbacks of Effient, which was launched in 2009, include a high rate of bleeding and lack of reversibility while other emerging agents in the ADP receptor antagonist class such as Brilinta and Novartis's elinogrel offer reversibility.
The report indicates that Effient will likely find greatest use in patient subgroups such as ST-segment elevation myocardial infarction patients, diabetics and patients who are at high risk of stent thrombosis but at modest risk of bleeding.
The report also reveals that generic erosion of premium-priced branded agents will offset sales of new agents and could cause the acute coronary syndrome market for drugs in the hospital setting to decrease from $800m in 2008 to $729m in 2018 in the US, France, Germany, Italy, Spain, the UK and Japan.
Twitter